NOT-TR-24-018: Notice of Change to Application Types Allowed in PAR-23-267 "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)"

Notice of Change to Application Types Allowed in PAR-23-267 "Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed)"

Notice Number:

NOT-TR-24-018

Key Dates

Release Date:

March 4, 2024

Related Announcements

April 18, 2023 - Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine (U43/U44 Clinical Trials Not Allowed). See NOFO PAR-23-267.

Issued by

National Center for Advancing Translational Sciences (NCATS)

Purpose

The purpose of this Notice is to change the application types allowed in PAR-23-267, Industrialization and Translation of Extracellular Vesicles for use in Regenerative Medicine, to include Renewal (Phase II) applications.

Part 2. Full Text of Announcement
Section II. Award Information

Currently reads:

Resubmission (All Phases)
New (Phase I)
New (Phase I, Fast-Track)
New (SBIR Direct Phase II)

Corrected to read (in bold italics):

Resubmission (All Phases)
New (Phase I, Fast-Track, Direct Phase II)
Renewal (Phase II)

All other aspects of the NOFO remain unchanged.

Inquiries

Please direct all inquiries to:

Christine Happel, Ph.D.
Office of Special Initiatives
National Center for Advancing Translational Sciences (NCATS)
Telephone: 301-827-9444
Email: christine.happel@nih.gov